SERIOUS PROBLEMS WITH METHOTREXATE?
Low dose methotrexate (5-25 mg/week) represents a major therapeutic advance in the management of RA in the last decade. Its established efficacy has led to it being used as the lead comparator drug in slow acting anti-rheumatic drug (SAARD) trials, to its increasing use in early disease, and to its inclusion in many drug combinations currently being evaluated. It seems to be the best tolerated SAARD with up to 75% remaining on it after 5 years [1] . Its therapeutic mode of action is still a matter of conjecture as low dose therapy is not anti-proliferative yet is still anti-inflammatory [2] . Its anti-inflammatory effect may be mediated by adenosine [3] although direct effects on cytokine and eicosanoid production have been claimed.
Methotrexate's pharmacodynamics vary, absorption and excretion differing enormously and unpredictably between individuals as well as being influenced by measurable factors such as renal function and concomitant therapies including NSAIDs and probenicid. The latter can elevate methotrexate levels by 400% [4] . This is important when assessing the relative efficacy and side effects in individual patients.
Minor adverse reactions with methotrexate are relatively common but generally do not result in treatment discontinuation. This contrasts with other SAARDs e.g. myocrisin, minor reactions to which often lead to stopping therapy when temporary cessation or dosage reduction, may be more appropriate [5] . Non lifethreatening methotrexate side effects such as nausea or diarrhoea may be improved by dosage adjustment, altering route of administration from oral to parenteral or using divided weekly dosage. Increased nodulosis is an unusual but well-recognized occurrence with methotrexate which can be troublesome. It has been reported to be helped by co-treatment with hydroxychloroquine [6] . Other less serious but troublesome adverse reactions such as minor stomatitis, alopaecia and skin rashes are self-evident and can be treated according to their severity by withdrawal of therapy, dosage adjustment or topical treatment. It has been suggested that methotrexate is associated with increased post-operative infections or delayed wound healing and that it should be stopped pre-operatively. Several small prospective studies have not confirmed such an effect [7, 8] , yet a definitive answer requires a much larger study.
The more potentially lethal adverse haematological, pulmonary and hepatic reactions seem to be associated with an older group, renal impairment and relative folate deficiency. There is some evidence that folate supplements cause no loss of efficacy and protect against toxicity [9] . Serious haematological toxicity seems to be relatively rare [10] and is usually treatable by folinic acid rescue. The relationship of serious haematological toxicity to co-administration with trimethoprim/sulphamethazole is established yet its 0263-7103/94/111001 + 06 $08.00/0 combination with another folate antagonist, sulphasalazine, has not shown the same problem [11] . One difficult problem facing the clinician is the patient on low dose methotrexate who develops dyspnoea. This may represent infection by a common respiratory pathogen, opportunistic infection (e.g. with Pneumocystis carinii), methotrexate pneumonitis, or an unrelated problem. Methotrexate pneumonitis is a potentially life-threatening complication, probably a hypersensitivity phenomenon, which is reversible on stopping treatment and giving steroids [12] . The pneumonitis appears not to be dose related. It is recommended that all patients have a pre-treatment chest X-ray (and possibly pulmonary function tests) to check for pre-existing lung disease. Another theoretical side effect of methotrexate is oncogenicity, but there is no clear evidence to indicate this as a problem [13] .
The clinician perhaps worries most about whether he is accumulating a cohort of rheumatoid patients who are developing irreversible liver damage. In last month's issue of the Journal [14] , three cases of cirrhosis are described in elderly male RA patients treated with methotrexate. All three patients had received over 3 g of methotrexate and their findings suggest an incidence of significant liver disease of 9.4/1000 at 5 yr as opposed to Walker et al. [15] who estimated an incidence of 1/1000 at 5 yr. The American College of Physicians recommended liver biopsy after 2-3 yr of methotrexate treatment which has been regarded by some as excessive [16, 17] . In some studies treatment discontinuation has been instituted if there was a sustained elevation of transaminases above three times the upper limit of normal [18] . Guidelines have recently been issued by the ACR based on expert analysis of published experience with methotrexate [19] . Prior to starting treatment alcohol consumption should be reviewed and restrictions on alcohol consumption stressed to the patient; baseline liver function tests, hepatitis B and C serological studies should be checked; pre-treatment liver biopsy should be considered in the presence of persistently raised transaminases, positive hepatitis serology or a history of alcohol abuse; liver function tests should be checked every 4-8 weeks throughout treatment. If transaminase levels are elevated in more than six of the 12-monthly (or five of nine if tests are 6-weekly) monitoring tests performed, liver biopsy or treatment discontinuation should be considered. While recognizing the differences in clinical practice between Europe and North America, there is a compelling argument that guidelines like these be considered mandatory because of the future potential medicolegal and resource implications. 
